A Phase 3, Randomized, Double-blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of HDM1002 Tablets Compared With Dapagliflozin in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
Latest Information Update: 31 Jul 2025
At a glance
- Drugs HDM 1002 (Primary) ; Dapagliflozin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Hangzhou Zhongmei Huadong Pharmaceutical
Most Recent Events
- 31 Jul 2025 New trial record